Morphologic and molecular heterogeneity in imatinib-resistant GIST

被引：0
|
作者：
Liegl, B.
Kepten, I.
Donsky, R.
Fletcher, C. D. M.
Corless, C. L.
Fletcher, J. A.
机构：
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Med Univ Graz, Graz, Austria
[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
来源：
LABORATORY INVESTIGATION | 2008年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
51
引用
收藏
页码：14A / 14A
页数：1
相关论文
共 50 条
  • [1] Morphologic and molecular heterogeneity in imatinib-resistant GIST
    Liegl, B.
    Kepten, I.
    Donsky, R.
    Fletcher, C. D. M.
    Corless, C. L.
    Fletcher, J. A.
    MODERN PATHOLOGY, 2008, 21 : 14A - 14A
  • [2] Sunitinib for imatinib-resistant GIST
    Joensuu, Heikki
    LANCET, 2006, 368 (9544): : 1303 - 1304
  • [3] The role of surgery in an imatinib-resistant GIST liver secondary
    Loots, E.
    SOUTH AFRICAN JOURNAL OF SURGERY, 2015, 53 (02) : 70 - 71
  • [4] A Imatinib-Resistant Metastatic GIST Tumor Manifests as Diffuse Pruritus
    Vital-Herne, Dimitri
    Li, Tian
    Huang, Xiaoyan
    Ferstenberg, Richard
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S1533 - S1534
  • [5] KIT hyperactivation in imatinib-resistant GIST: Implications for salvage therapies.
    Bauer, S
    Hubert, C
    Heinrich, MC
    Cohen, P
    Bertagnolli, M
    Demetri, GD
    Fletcher, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 824S - 824S
  • [6] Clinical experience with perioperative sunitinib and extensive resection of imatinib-resistant metastatic gist
    Raut, C.
    Morgan, J.
    Quigley, M.
    George, S.
    Wagner, A.
    Demetri, G.
    Bertagnolli, M.
    ANNALS OF ONCOLOGY, 2007, 18 : VII123 - VII123
  • [7] Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor
    Huang, Wen-Kuan
    Gao, Jiwei
    Chen, Ziqing
    Shi, Hao
    Yuan, Juan
    Cui, Huanhuan L.
    Yeh, Chun-Nan
    Branstrom, Robert
    Larsson, Catharina
    Li, Shuijie
    Lui, Weng-Onn
    CELLS, 2020, 9 (06)
  • [8] Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
    Sako, Hiroyuki
    Fukuda, Kazumasa
    Saikawa, Yoshiro
    Nakamura, Rieko
    Takahashi, Tsunehiro
    Wada, Norihito
    Kawakubo, Hirohumi
    Takeuchi, Hiroya
    Ohmori, Tai
    Kitagawa, Yuko
    PLOS ONE, 2014, 9 (09):
  • [9] Evaluating boron neutron capture therapy as a Novel Treatment Strategy for Imatinib-resistant GIST
    Hagihara, Seita
    Arima, Jun
    Taniguchi, Kohei
    Inomata, Yosuke
    Asakuma, Mitsuhiro
    Tomiyama, Hideki
    Suzuki, Minoru
    Lee, Sangwoong
    CANCER SCIENCE, 2025, 116 : 1008 - 1008
  • [10] Regorafenib as second-line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST)
    Takahashi, Tsuyoshi
    Nishida, Toshirou
    Kudo, Toshihiro
    Boku, Narikazu
    Honma, Yoshitaka
    Komatsu, Yoshito
    Nakatsumi, Hiroshi
    Matsumoto, Koji
    Onoe, Takuma
    Oki, Eiji
    Nakamoto, Masako
    Fukutani, Miki
    Nomura, Shogo
    Sato, Akihiro
    Naito, Yoichi
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345